Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1 by unknown
Zhu et al. Journal of Translational Medicine 2014, 12:352
http://www.translational-medicine.com/content/12/1/352RESEARCH Open AccessStreptavidin-biotin-based directional double
Nanobody sandwich ELISA for clinical rapid and
sensitive detection of influenza H5N1
Min Zhu1, Xue Gong1, Yonghong Hu3, Weijun Ou2 and Yakun Wan1,2*Abstract
Background: Influenza H5N1 is one subtype of the influenza A virus which can infect human bodies and lead to
death. Timely diagnosis before its breakout is vital to the human health. The current clinical biochemical diagnosis
for influenza virus are still flawed, and the diagnostic kits of H5N1 are mainly based on traditional monoclonal
antibodies that hardly meet the requirements for clinical applications. Nanobody is a promising tool for diagnostics
and treatment due to its smallest size, high specificity and stability. In this study, a novel Nanobody-based bioassay
was developed for rapid, low-cost and sensitive detection of the influenza H5N1 virus.
Methods: Nanobodies specific to H5N1 virus were selected from a VHH library by phage display technology. In this
system, the biotinylated Nanobody was directionally captured by streptavidin coated on ELISA plate, which can
specifically capture the H5N1 virus. Another Nanobody conjugated with HRP was used as a detector. A novel
directional enzyme-linked immunosorbent assay for H5N1 using specific Nanobodies was established and compared
to the conventional undirected ELISA assay.
Results: We have successfully constructed a high quality phage display Nanobody library and isolated two
Nanobodies against H5N1 with high affinity and specificity. These two Nanobodies were further used to prepare
the biosensor detection system. This streptavidin-biotin-based directional double Nanobodies sandwich ELISA for
H5N1 detection showed superiority over the commonly undirectional ELISA protocol. The linear range of detection
for standards in this immunoassay was approximately 50? 1000 ng/mL and the detection limit was 14.1 ng/mL. The
average recoveries of H5N1 virus from human serum samples were in the range from 94.58% to 114.51%, with a
coefficient of variation less than 6.5%.
Conclusion: Collectively, these results demonstrated that the proposed detection system is an alternative
diagnostic tool that enables a rapid, inexpensive, sensitive and specific detection of the influenza virus.
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Influenza virus is a member of the group of single-
stranded ribonucleic acid (ssRNA) viruses with negative
polarity. It belongs to the family Orthomyxoviridae and
contains three genera: influenza A, influenza B and in-
fluenza C [1,2]. Avian influenza A is a severe infectious* Correspondence: ywansystemsbiology@gmail.com
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unless otherwise stated.disease that occurs and spreads very fast in poultry, wild
birds, animals and it is transmissible to humans [3]. Ac-
cording to the antigenicity of their hemagglutinin (HA)
and neuraminidase (NA) molecules, the influenza A vi-
ruses have been classified into 16 HA subtypes (H1-H16)
and 9 NA subtypes (N1-N9) [4,5]. Avian influenza H5N1
virus, a subtype of influenza A virus, has been considered
as a potential highly pathogenic virus threatening human
health [6]. Since the first human infected with influenza
H5N1 in Hong Kong, in 1997 [7], more than 300 cases of
death in fifteen countries have been reported by the World
Health Organization (http://www.who.int/en/). The mostis an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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severe influenza syndrome, associated with symptoms of
fever, cough, short breath and radiological evidence of
pneumonia [8]. The influenza H5N1 have seriously im-
pacted both global economy and human health, therefore
a rapid and sensitive detection of the H5N1 virus is of
great significance.
The rapidly and precisely diagnose the subtype of influ-
enza virus when it breaks out, a variety of methods for
detection of the influenza virus have been reported in nu-
merous studies. Virus isolation [9], immunofluorescence
[10], polymerase chain reaction (PCR) [11,12], enzyme-
linked immunosorbent assay (ELISA) [13] and serological
methods are becoming more commonly available in diag-
nosis. However, these conventional methods are laborious,
time-consuming, expensive and require appropriate labora-
tory facilities. For example, virus isolation was regarded as
the gold standard for diagnosis and also indispensable for
rapid laboratory confirmation of human influenza in rou-
tine, however it often require 5? 7 days to test with labor-
intensive and long procedures [14]. Another novel method
for a rapid and dependable testing of influenza is the use of
biosensors. Microgravimetric quartz crystal microbalance
(QCM) has been considered as a transducer for virus de-
tection such as influenza A and B viruses [15], but the sen-
sitivity and detection limit of QCM immunosensors are
unsatisfactory. Thus, the development of an inexpensive
and sensitive method for influenza detections a challenge
for scientists all over the world.
The detection of virus particles by antibody-mediated
immunoassays is specific and accurate. Monoclonal anti-
bodies (mAbs) against viral proteins were established for
the immunological detection of H5N1 influenza virus
for research and diagnostic purposes [16]. Nevertheless,
traditional monoclonal antibodies used in virus detection
need more support costs and they are difficult for
massive production. A single variable domain, also called
Nanobody? (a trademark of Ablynx NV) or the variable
domain of heavy-chain only antibody (VHH), was derived
from the heavy chain antibody present in camels, llamas,
alpacas and sharks [17,18]. The single domain VHH is the
smallest available, functional and intact antigen-binding
fragment, only with approximately 15 kDa. Because the
VHH prefers to associate with concave-shaped epitopes, it
can recognize more inaccessible and cryptic sites, when
compared to the conventional antibodies [19]. Several
VHHs have been used as new bio-medicine for therapy
and evaluated in phase I and II clinical trials by Ablynx
(http://www.ablynx.com/). Moreover, Nanobodies are eas-
ily expressed in large quantities, and have excellent stabil-
ity and high affinity with the target antigen [20]. Based on
these eminent properties, Nanobodies used in diagnosis
will demonstrate infinite advantages. In our previous stud-
ies, Nanobodies against human procalcitonin (PCT) weresuccessfully applied to the basis of signal amplification
of CdTe@SiO2/NbII detection [21]. The PCT could re-
spond as low as 3.4 pg/mL and showed very high sensitiv-
ity. Additionally, we have developed the human prealbumin
(PA) Nanobody-based flow injection chemiluminescence
immunoassay for the detection of PA with a limit of
0.01 μg/L [22].
In this study, we have successfully constructed an im-
mune phage display VHHs library against influenza
H5N1 virus with the size of 5 ? 10 8 colonies. The VHHs
recognized two different epitopes of H5N1 virus particle
were used for biosensor detection system. As shown in
Scheme 1, the biotinylated Nanobody was captured dir-
ectionally by streptavidin coated on ELISA plates and
another HRP-conjugated Nanobody was used as a de-
tector. This streptavidin-biotin-based directional double
Nanobody sandwich ELISA to detect the serum samples




The influenza H5N1 virus used in this study was ob-
tained from the Shanghai Institute of Biological Products
(China). Freund ? s complete adjuvant and Freund ? s in-
complete adjuvant were purchased from Sigma-Aldrich
(USA). Fast Track 2.0 Kit was provided by Invitrogen
(USA) and OligodT primer was obtained from Thermo
Scientific (USA). Restriction enzymes Pst I, Not I, Nco I
and BstE II were provided from NEB (USA). The mouse
anti-HA tag antibody was purchased from Covance (New
Zealand). The anti-mouse IgG-alkaline phosphatase, bis
phosphate and His-select column were purchased from
Sigma-aldrich (USA). The D-biotin and horseradish perox-
idase (HRP) were purchased from Bio Basic Inc. (China).
The Streptavidin Mutein Matrix was purchased from
Roche (Switzerland). The microtiter plate was purchased
from Thermo Scientific NUNC (Denmark). The Beaver-
Nano? Streptavidin Matrix Coated 96-Well plates were
provided by BeaverNano technology company (China).
The VCSM13 helper phages, TG1 cells, WK6 cells, plasmid
pBAD and plasmid pBirA were obtained from Prof. Serge
Muyldermans? s lab (Laboratory of Cellular and Molecular
Immunology, Vrije Universiteit Brussel, Belgium).
Immunization and construction of the Nanobody library
A healthy young Bactrian camel (Camelus bactrianus) was
immunized with inactivated influenza H5N1 virus (1 mL,
100 μg) mixed with an equal volume of Freund? s complete
adjuvant for the first time, and with the same volume of
Freund? s incomplete adjuvant for the next five times [23].
The camel was injected for once a week to stimulate
antigen-specific B cells to express heavy chain antibodies.
After the last injection, peripheral blood lymphocytes
Scheme 1 Schematic illustration of strategies to select the H5N1-specific VHHs and to apply the detection functions. The H5N1-specific
VHH genes were selected from an immunized dromedary. Nanobodies identified different epitopes were used to couple with biotin or HRP for
detecting. Biotinylated Nanobody was directionally captured by streptavidin in microtiter plate. The attachment of H5N1 virus was followed by
the attachment of biotinylated Nanobody onto streptavidin. Another Nanobody conjugated with HRP was used as a detector. The measurements
were taken at absorbance of 450 nm.
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library construction. All camel experiments were per-
formed according to guidelines approved by the Southeast
University.
For library construction, total mRNA was extracted
from about 107 lymphocytes and 40 μg of mRNA were
used to synthesize the cDNA with the oligodT primer. To
avoid contamination with the VH genes, the variable re-
gions of the VHH were amplified by nested PCR. The first
PCR was performed using the first-strand cDNA as tem-
plate with the primers CALL001 and CALL002 [24]. This
protocol consisted of an initial denaturation step at 94?C
for 7 min, followed by 30 cycles of (94?C for 1 min, 55?C
for 1 min, and 72?C for 1 min) and a final extension stepat 72?C for 10 min. The PCR products consisting
of ~700 bp fragments were purified by agarose gel elec-
trophoresis and used as template for a second PCR.
The primers framework-1 and framework-2 are used to
amplify the Nanobodies repertoire and the final prod-
ucts of ~400 bp were extracted by agarose gel purifica-
tion [25]. The purified second PCR product fragments
were ligated into the phagemid pMECS after digestion
with the restriction enzymes Pst I and Not I, and then
electro-transformed into competent E.coli TG1 cells. The
transformants were cultured on solid 2 ? YT medium con-
taining 2% glucose and 100 μg/mL ampicillin at 37?C
overnight. The capacity of the constructed library was
measured by the number of colonies after a gradient
Zhu et al. Journal of Translational Medicine 2014, 12:352 Page 4 of 10
http://www.translational-medicine.com/content/12/1/352dilution. Then examine the insertion rate of the con-
structed library by PCR amplification.
Library screening by phage display
The Nanobodies against H5N1 virus were selected by
phage display. The VHHs were selected on their target
coated proteins and enriched by three consecutive rounds
of bio-panning, with the infection of VCSM13 helper
phages. Inactivated influenza H5N1 virus (20 μg) was
coated onto the microtiter plates at 4?C overnight. After
blocking with 0.1% casein in phosphate-buffered saline
(PBS) for 2 hours, the microtiter plates incubated with
phage-displayed VHHs in PBS for 1 h at room temperature.
The specific phages were eluted with 100 mM triethyla-
mine, for 10 minutes at room temperature, and then im-
mediately neutralized with 1.0 M Tris? HCl (pH 7.4).
Then, the eluted phages were plated at various dilutions
and incubated with TG1 cells for infection. The helper
phagesVCSM13 were added to rescue the phages. This
process represented one round of panning and the gener-
ated phage particles were used in the next round of pan-
ning. After three rounds of panning, the H5N1-specific
phages were enriched gradually.
95 individual colonies were randomly selected from
each round of panning and cultured in TB medium with
100 μg/mL amplicillin. The Nanobodies were expressed
by induction with 1 mM Isopropyl β-D-1-Thiogalactopy-
ranoside (IPTG). The positive clones expressing H5N1-
specific Nanobodies were identified by performing a
periplasmic extract ELISA (PE-ELISA). The supernatants
of cells collected after an osmotic shock were transferred
into the microtiter plate wells, previously coated with
the H5N1 virus. Then mouse anti-HA tag antibody was
added and incubated for 1 h, followed by a similar incuba-
tion with anti-mouse IgG-alkaline phosphatase for 1 h.
After washing the microtiter plates with PBST (PBS with
0.05% Tween-20), the chromogenic solution containing
Bis phosphate (pNPP) was added and after a few minutes
the absorbance at405 nm was read. Finally, the positive
clones were sequenced and classified into different families
based on the diversity of the amino acids sequence in the
CDR3 region (complementary determining region).
Expression and purification
The identified VHH genes of positive clones were electro-
transformed into E.coli WK6 cells to express Nanobodies.
The cells were cultured in TB medium supplemented with
0.1% glucose, ampicillin (100 μg/mL) and 2 M MgCl2 at
37?C. Once the optical density r eached 0.6-0.9, the cultures
were induced with the addition of 1 mM IPTG and incu-
bated at 28?C overnight. The periplasmic extract proteins
were released by osmotic shock and purified by immobi-
lized metal affinity chromatography (IMAC) using NI-NTA
superflow sepharose columns with gradient concentrationsof imidazole in PBS solution. The purified Nanobodies were
analyzed by SDS-PAGE and dialyzed in PBS buffer.
Specificity detection
To detect the specificity of the purified Nanobodies, sev-
eral kinds of avian influenza virus were used for testing
via ELISA assay. 5 μg/mL of each subtype of influenza
virus were coated onto microtiter plates overnight at 4?C
and blocked with 1% BSA at room temperature for 2 h.
10 μg/mL Nanobodies were added and incubated at
room temperature for 1 h. The detection steps were per-
formed by using the mouse anti-HA tag and the rabbit
anti-mouse IgG-alkaline phosphatase conjugated anti-
bodies were the same as the ones performed during the
periplasmic extract ELISA described above.
The Nanobody biotinylatedin vivo and conjugated with
HRP
The genes encoding the H5N1-specific VHH were sub-
cloned into the plasmid pBAD by Nco I and BstE II
restriction endonucleases. The recombinant plasmids
were co-transfected into WK6 cells with another plasmid,
the pBirA plasmid. The VHH-BAD fusion proteins were
induced with 1 mM IPTG followed by the addition of
50 μM D-biotin to the medium for 30 min. The periplas-
mic proteins were extracted performing the osmotic shock
protocol and the biotinylated Nanobody was purified by
Streptavidin Mutein Matrix and eluted with a 6 mM
D-biotin solution.
To make the Nanobodies play a detecting role, horse-
radish peroxidase (HRP) was coupled to them. The coup-
ling was performed by adding 0.1 M fresh NaIO4 into
5 mg/mL HRP for 30 min at 4?C followed by the addition
of 2.5% ethylene glycol and incubation for 30 min at room
temperature. Next 1 mg of H5N1-specific Nanobodies
were added and incubated overnight at 4?C. After the
overnight incubation sodium borohydride (5 mg/mL) was
added for 3 h at 4?C, followed by dialysis into PBS. To
check the efficiency of enzyme labeled Nanobodies, 5 μg/
mL of H5N1 antigen were coated and 10 μg/mL of Nano-
bodies coupled with HRP were used as detectors to
perform the ELISA experiment. Chromogenic reactions
were proceeded with 3, 3′, 5, 5′-Tetramethylbenzidine for
10 minutes and stopped by addition of 2 M H2SO4, the
absorbance was measured at 450 nm.
Double Nanobodies sandwich ELISA
Directional double Nanobodies sandwich ELISA was per-
formed based on streptavidin-biotin system. 1 μg/mL of
biotinylated Nanobodies were added into streptavidin
matrix coated plate and incubated at room temperature
for 1 h. Several concentrations of H5N1 virus (0, 10, 50,
100, 500, 1000, 5000 ng/mL) were added for 2 h after
blocked with 5% BSA for 1 h. The Nanobodies conjugated
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bated with captured H5N1 virus for 1 h. Finally, the mea-
surements of chromogenic reaction were read at 450 nm.
For the undirectional double sandwich ELISA, unbioti-
nylated Nanobody was used as a capturing Nanobody and
coated onto a conventional microtiter plate. Seven con-
centrations of H5N1 virus (0, 10, 50, 100, 500, 1000 ng/
mL) were used to test this system. After blocking, antigen
reaction and Nanobody-HRP reaction, the chromogenic
reaction was measured at 450 nm.
Recovery test
The directional sandwich ELISA was used for H5N1
virus detection in human serum samples. 5 concentra-
tions of H5N1 virus in linear range (50, 100, 250, 500,
1000 ng/mL) were added into human serum sample to
test the directional system. Each concentration was rep-
licated three times.
Results
Immunized VHH library construction
The VHH library was constructed after immunization of
a healthy camel with the H5N1 virus for 7 weeks. These
H5N1 viruses were isolated from eggs and inactivated by
gamma radiation. The total IgG titer of serum reached
to 1:1000 after the last immunization and it was consid-
ered that it had raised good immunogenic response.Figure 1 Library construction. (A) The size of the library was determined
library size was 5 x 108 cfu/mL. (B) 24 colonies were randomly selected to
products was approximately 400 bp.The nested PCR assured the accuracy and feasibility of
the whole reaction. The first PCR products contained
the 700 bp fragments of the VH-CH2 exons, and were
the templates for the second PCR that generated prod-
ucts of 400 bp fragments for the VHH exons.
To construct the library, Pst I and Not I sites were intro-
duced in the 5′ and 3′ ends of the VHH fragments, respect-
ively. 4.8 μg of digested VHH fragments and 16 μg of
linearized pMECS vector were used for ligation. The con-
nection products were transformed into TG1cells by 30
electroporation transformations. The titer of this Nanobody
library against H5N1 was calculated by counting the num-
ber of colonies in gradient dilution plates (Figure 1A). The
titer reached to 5 ? 10 8 cfu/mL meaning that it was highly
possible to obtain Nanobodies with high specificity and se-
quence diversity. Another parameter of quality control
from the library is to check the insertion rate. 24 colonies
were randomly chosen for PCR analysis and the percentage
of library insertion rate was 100% as shown in Figure 1B.
These results indicated that we have successfully con-
structed an immune phage display library with high quality
for the following H5N1-specific Nanobodies selection.
Library screening and selection of H5N1-specific
Nanobodies
Bio-panning was performed to isolate the H5N1-specific
Nanobodies after a high quality phage display library wasby counting the number of clones after gradient dilution and the
estimate the correct insertion rate by performing PCR. The size of
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and used for incubation with H5N1 virus particles. The
phages expressing H5N1-specific VHHs were enriched by
consecutive rounds of bio-panning on H5N1. Compared
with the negative control, the specific VHHs enriched 200-
fold after three rounds of panning (Figure 2A).
Then, 95 colonies randomly picked up from each
round were screened for influenza H5N1 virus recogni-
tion by periplasmic extraction followed by ELISA. The
cultured cells were disrupted by osmosis in our protocol,Figure 2 Nanobodies against H5N1 were selected by phage display li
enriched about 200-fold after three rounds of panning. (B) Periplasmic extract
positive clones. The ratio higher than 2 was considered as positive. (C) Three kiallowing the Nanobodies to be collected in the super-
natant and followed by incubation with antigen. Thus,
we called this assay a periplasmic extraction ELISA
(PE-ELISA). As shown in Figure 2B, 26 colonies were
found to specifically bind H5N1 virus but not the
negative blank control. Here we often identified the
positive clones whose binding ratios more than 2. Ac-
cording to our previous studies [21,22,26], high enrich-
ment within the 2 ? 4 rounds of panning for common
antigen will benefit and the majority of specific VHHsbrary. (A) The enrichment was detected and H5N1-specific VHHs were
ELISA for 95 clones for detecting and 26 clones were identified as the
nds of different amino acid sequences of anti-H5N1 VHHs were identified.
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[27].
After identified positive clones by PE-ELISA, the se-
quence of 26 clones was analyzed and divided into
three families. Their paratope (CDR3 region) amino
acid sequences differed by some amino acids as shown
in Figure 2C.Figure 4 Specificity detection of three Nanobodies against
H5N1 by ELISA. Different subtypes of influenza viruses were coated
onto microtiter plates and the Nanobodies were added to incubate
with them. After the reaction with the mouse anti-HA tag antibody
and then with the rabbit anti-mouse IgG-alkaline phosphatase, the
chromogenic solution containing bis phosphate were added and
the absorbance was measured by an ELISA reader at 405 nm. The
values were the means of three replicates. Nb7 and Nb93 only
recognized H5N1 virus but not other subtypes.Expression of the Nanobodies and specificity detection
The Nanobodies expressed in WK6 E.coli cells were
fused with pelB leader signal sequence and the soluble
Nanobodies were further purified by Ni-NTA Superflow
Sepharose columns. Sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) analysis demon-
strated the high quality of the Nanobodies, with more
than 90% purity obtained (Figure 3A). Moreover, milli-
gram quantities of production were yielded (Figure 3B).
The specificity of these Nanobodies was demonstrated
by ELISA. The results in Figure 4 showed that Nano-
body NO.16 (Nb16) not only specifically binds to H5N1
but also to H1N1 viruses. Nanobody NO.7 (Nb7) and
NO.93 (Nb93) were shown to bind specifically to the
H5N1 virus but not to the other subtypes of influenza A
viruses. Based on these results, Nb7 and Nb93 were used
for the Nanobody-pairing assay. The Nanobody-pairing
assay was performed from these three H5N1-specific
Nanobodies. It turned out that Nb7 and Nb93 could
greatly combine with H5N1 virus particles for the fur-
ther diagnostic application based on sandwich ELISA.Nanobody biotinylation based on in vivo assay
In order to execute Nanobody biotinylation, VHH genes
were sub-cloned into pBAD17 vector containing a Biotin
Acceptor Domain (BAD), at the downstream of the VHH
sequence. Then, the recombinant plasmids were co-
transformed into WK6 cells with another plasmid pBirA
(encoding biotin protein ligase) to express biotinylatedFigure 3 Purification of H5N1-specific Nanobodies. (A)Three Nanobodi
affinity chromatography (IMAC) using a His-Select matrix. These Nanobodie
Isoelectric point, molecular weight and output of three Nanobodies.Nanobodies. This method labeled Nanobody with biotin
in vivo will not disrupt the combination between Nanobo-
dies and antigen. Nb7 was chosen for conjugation with
biotin and another one, Nb93, was used as a detector to
couple with HRP. The biotinylated Nanobodies were ex-
tracted from the periplasm of cells by osmotic shock as
described previously and further purified with only 200 μL
Streptavidin-Mutein Matrix repeated seven times. It was
produced at a final yield of 2.1 mg/L culture.Streptavidin-biotin-based directional double Nanobodies
sandwich ELISA
The result of this streptavidin-biotin-based directional
double Nanobodies sandwich ELISA was shown as
Figure 5A. Under the optimal conditions, seven gradient
concentrations (from 0 to 5000 ng/mL) were performed in
our detection. The absorbance at 450 nm displayed a goodes encoded by different sequence were purified by immobilized metal
s were detected by coomassie brilliant blue stained SDS-PAGE. (B)
Figure 5 Detection of H5N1 virus by directional sandwich ELISA and comparison with the conventionally undirectional ELISA. (A) Serial
concentrations (0, 10, 50, 100, 500, 1000, 5000 ng/mL) of H5N1 antigen were used for detection. The linear relationship in the range from 50 to
1000 ng/mL. The linear equation was calculated as Y = 0.0006 X + 0.1640 with an acceptable correlation coefficient of 0.9947 (R2). The data
represent mean ? standard deviation from triplicate measurements. (B) The concentration of H5N1 from 0 to 1000 ng/mL to test directional and
undirectional sandwich ELISA system. Error bars are standard deviations of three measurements.
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range from 50 to 1000 ng/mL. The linear equation was
calculated as Y = 0.0006X + 0.1640 with an acceptable cor-
relation coefficient of 0.9947 (R2). The detection limit of
this method for H5N1 virus was 14.1 ng/mL. However, as
shown in Figure 5B, the unbiotinylated Nanobodies dir-
ectly coated in microtiter plate to capture H5N1 virus and
detected by Nb-HRP did not show a good linearship from
50 to 1000 ng/mL. Only the concentration of H5N1 viruswith 500 ng/mL can be detected. Overall, the directional
system showed an excellent sensitivity than the undirec-
tional ELISA.
Finally, sample matrix effects were examined by sample
dilution with buffer. Serum samples were added with H5N1
virus at different concentrations (50? 1000 ng/mL) and
assayed by directional ELISA. The recoveries of H5N1 virus
from human serum samples are shown in Table 1. The
average recoveries from triplicate measurements ranged
Table 1 Streptavidin-biotin-based directional ELISA for
H5N1 detection in serum samples
Sample H5N1 concentation (ng/ml) Recovery RSD
Added Found (%) (%)
1 50 47.29 94.58 4.24
2 100 114.51 114.51 4.13
3 250 253.18 101.27 6.23
4 500 488.65 97.73 2.72
5 1000 952.80 95.28 2.14
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(RSD) less than 6.5%. This result indicated that directional
double Nanobodies sandwich ELISA based on streptavidin-
biotin system could effectively detect influenza H5N1 virus
in real samples. It may provide promising diagnostic mate-
rials for clinical application.
Discussion
In our study, the VHH fragments encoding three kinds of
H5N1-specific Nanobodies in phage plasmid pMECS were
directly transformed into WK6 E.coli cells. Unique proper-
ties made these cells cannot suppress the amber stop codon
between gene III and VHH from pMECS [28]. Moreover,
the Nanobodies expressed in WK6 E.coli cells were fused
with pelB leader signal sequence [28]. These Nanobodies
with pelB leader signal peptide will be only expressed in the
periplasmic space. Thus, all the Nanobodies were present
in the supernatant when the cells were disrupted by osmos-
tic shock. However, the conventional method is to sub-
clone the VHH fragment from the phagemid into an
expression plasmid [27]. The present method is more con-
venient that we do not necessary to do sub-cloning step.
It is well known that the binding of biotin to streptavidin
is one of the strongest non-covalent interactions known in
nature [29]. The complex of biotin-streptavidin can resist
some severe environments such as organic solvents, pro-
teolytic enzymes and extremes of temperature and pH
[30]. Therefore, this system can be used extensively in mo-
lecular biology and bionanotechnology. In immune detec-
tion systems, streptavidin is usually directly immobilized
on the sensor chip, magnetic bead, electrode and so on.
However, these methods usually need high quality of both
materials and instruments. In order to make a rapid, inex-
pensive and accurate detection of H5N1, we choose the
microtiter plate to perform this assay. As shown in
Scheme 1, biotinylated Nanobodies were directionally cap-
tured by streptavidin which was previously coated on a
microtiter plate. High density of streptavidin can bind
more biotinylated Nanobodies. These Nanobodies evenly
aligned and emerged antigen binding site. When H5N1
virus was recognized and captured by biotinylated Nano-
body, another Nanobody coupled with HRP was used for
detection.Avian influenza H5N1 is a potential highly pathogenic
virus threatening to human health. However, current
clinical biochemical diagnosis for influenza virus are still
flawed, and the diagnostic kits of H5N1 commercially
available are mainly based on the traditional monoclonal
antibody to hardly meet requirements of the clinical ap-
plication. The limitation of detection using this method
is lower than the reported research using traditional
monoclonal antibody [16], Moreover, current commer-
cial diagnostic kits for influenza viruses from Binax, Inc.
showed the LOD were approximately 100 ng/mL (http://
www.biomedix.com.br/bulas/binax). However, the nov-
elty directional ELISA based on biotinylated Nanobody
showed the superiority than conventional undirectional
ELISA. Moreover, Nanobodies used in this study are
highly specific, high-yield and stable. These advantages
will be made a lower cost and highly sensitivity for the
promising diagnostic kits.
Conclusions
In this study, we successfully selected Nanobodies against
H5N1 virus from a high quality library and developed a dir-
ectional, rapid and sensitive immunoassay for H5N1 virus
detection based on Nanobodies. Directional double Nano-
body sandwich ELISA based on streptavidin-biotin system
showed higher sensitivity than conventionally undirectional
sandwich ELISA. It demonstrated that the proposed detec-
tion system is an alternative way to enable rapid, low-cost
and highly specific detection of H5N1 virus and may be
easily applied for the detection of other subtypes of influ-
enza virus or any other proteins.
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